Voyager announces CTAD posters for Voyager Therapeutics stock

Published on 10/29/2026 at 13:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Two Alzheimer presentations are planned for November 16, 2026 and November 17, 2026. Voyager Therapeutics stock costs EUR 1.64 on October 29, 2026.

Clinical dates and cash position

Voyager's VY1706 and VY7523 posters are scheduled for November 16, 2026.
The company's cash position stood at USD 149.0 million at the end of the second quarter of 2026.
Initial acute safety data for VY1706 are anticipated in the first quarter of 2027, pending enrollment.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics (ISIN US92915B1061) announced two poster presentations for the Clinical Trials on Alzheimer's Disease conference on October 27, 2026. GlobeNewswire reported that the company will present work on VY1706 and VY7523 in Boston in November. The update gives the pipeline two clinical milestones to track.

Two programs reach the conference

VY1706 is Voyager's investigational gene therapy designed to lower tau production in the brain. VY7523 is a clinical-stage monoclonal antibody directed against the C-terminal region of tau. The programs address early Alzheimer's disease through different approaches, making the conference schedule relevant to both the gene therapy and antibody pipelines.

The first poster covers the first-in-human study design for VY1706, while the second describes baseline characteristics from a multiple ascending dose study of VY7523. Both presentations are listed as Phase I or Phase IIA work in the company announcement.

What does the leadership plan add?

Voyager appointed Robin Swartz president effective October 20, 2026 and expects her to succeed Alfred W. Sandrock as chief executive officer in the first quarter of 2027 after initial acute safety data from VY1706. The leadership plan therefore links a management transition to a clinical milestone. GlobeNewswire reported that Sandrock is expected to remain chief executive officer through the safety update and later continue on the board.

Voyager ended the second quarter of 2026 with USD 149.0 million in cash and reported USD 3.2 million of revenue for the period. The financial position supports a development timeline that extends into 2027, but enrollment and clinical safety remain important execution factors.

Dates for the clinical pipeline

The VY1706 poster is scheduled for November 16, 2026, while the VY7523 poster is also listed for November 16, 2026. The presentation windows run through November 17, 2026, giving investors two dated points for reviewing the company's Alzheimer programs.

Stock indication and investor context

Voyager Therapeutics stock was trading at EUR 1.64 at Lang & Schwarz on October 29, 2026 at 1:09 p.m. CET. No dated Xetra closing value was available for the comparison calculation, so the daily percentage change is not stated. The primary listing is Nasdaq, where the finance snapshot showed a USD 113.4 million market capitalization as of October 28, 2026.

The further course of trading is shown by the continuously updated real-time quote of Voyager Therapeutics stock.